February 2025

APSARD News & Updates

Catch up on all the latest posts in our News & Updates. Read one of the latests -

FDA Approves Johnson & Johnson Nasal Spray for Depression

As a follow up to his ADHD 201 at the APSARD Annual Conference on comorbidities, APSARD President interviewed on CNBC for a breakthrough depression indication. 

Relive the Best Moments from APSARD 2025

Missed the conference in San Diego? No problem, you can still register and claim enduring CE's until February 19th!

Attended the conference but missed some sessions? The recordings are available on the APSARD Hub and you can still claim CEs as well!

IMPORTANT NOTES: Completing the evaluation is required to claim CEs but do NOT complete until you have viewed all the sessions you want to claim!

Noven Debuts Optional Companion App for Patients with ADHD – Mindful Patch – at APSARD 2025 

XELSTRYM, The First-and-Only Amphetamine Patch for the Treatment of ADHD in adults and children 6+ Now Comes with an Optional Support App